secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2022-03-14T23:59:59+00:00
Accession:  0001818331-22-000034
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 2.02, 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sema4 announces non-reliance on previously issued financial statements and reports Q4 2021 results
--------------------------------------------------------------------------------

- Non-reliance on previously issued financial statements for years ended Dec 31, 2020 and 2019 due to expense classification errors in cost of services and selling & marketing.
- Identified adjustments in cost of services recognition for Q1-Q3 2021; restated financials to be included in 2021 10-K filed March 14, 2022.
- Q4 2021 test volumes (ex-COVID) up 37% YoY; total revenue $57.8M, net loss $40.2M vs $125.7M loss in prior year.
- Full year 2021 revenue $212.2M up from $179.3M; net loss $245.4M vs $241.3M.
- Reiterates FY2022 revenue guidance $215-225M; expects to close GeneDx acquisition by end of Q2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833122000034/0001818331-22-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833122000034/smfr-20220310.htm
  HTML page:      https://secwatch.observer/filing/0001818331-22-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer